When Psychological Trauma Becomes Systemic: PTSD as an Inflammatory Condition

PTSD is usually discussed as a disorder of memory and emotion. But a review by Yang and colleagues shows carefully and consistently that behind the psychological picture lies persistent immune dysregulation and systemic inflammation. This is not a figurative comparison, but a physiological reality: people with PTSD are more likely to have elevated levels of pro-inflammatory markers like IL-1β, IL-6, TNF-α, and C-reactive protein, and their immune cells themselves demonstrate shifts in activation and ‘tuning’. It is important to highlight not only the fact of increased inflammation but also how it is maintained and consolidated over time. The review brings together data from clinical and experimental work: from peripheral blood and saliva to neuroinflammation in the central nervous system.

The key to understanding this picture is that the body’s stress response is not limited to the brain. The hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenal-medullary (SAM) system trigger an avalanche of signals, and if the stress is short-lived, it helps us to survive. If, however, a person has experienced trauma and remains in a state of chronic tension, the physiological ‘brakes’ begin to fail. The review highlights the phenomenon of glucocorticoid resistance: in PTSD, cells become less responsive to cortisol, and the anti-inflammatory effect of this hormone is weakened. In parallel, sympathetic activation dominates, while the vagus nerve, conversely, is suppressed, which means more active NF-κB and sustained production of cytokines. In other words, the body itself keeps throwing fuel on the fire of inflammation.

Immune dysregulation in PTSD: from the blood to the microglia

Looking at the immune system in close-up, two layers of change are visible. The first concerns innate immunity: in some patients, the proportion of pro-inflammatory monocytes increases, and the functionality of neutrophils and natural killer (NK) cells changes. These cells are the first to respond to a threat and set the tone for the entire immune scene. The second layer affects adaptive immunity: a shift in the T-cell balance towards effector and memory cells is often noted, with a relative deficit of regulatory T-cells (Tregs). Such a profile supports long-term inflammation and makes the system ‘hypervigilant’ even in the absence of real danger. The authors of the review are cautious: not all studies agree on the details, but the general vector is the same — for some people with PTSD, inflammation is not an episode, but a background state.

Equally important is that the inflammatory signal reaches the brain. Microglia — the immune cells of the central nervous system — are sensitive to peripheral cytokines and to stress neurotransmitters. Their activation alters the function of astrocytes, disrupts synaptic plasticity, and complicates fear extinction. This makes memories “sticky” and makes it harder to learn new, safe patterns of reaction. The review emphasises that neuroinflammation is not necessarily the same for everyone — there are likely phenotypes with hyper- and hypo-activation, different phases post-trauma, and the influence of comorbidities like sleep issues, metabolic disorders, and infections.

On the horizon, genetic and epigenetic factors are also discernible. Polymorphisms in inflammatory response genes (for example, regions associated with TNF and CRP) are associated with greater symptom severity, while the methylation of promoters for interleukins and innate immunity receptors in some groups of trauma survivors is a reminder of how gene expression is ‘tuned’ by long-term stress. These findings do not imply a “gene of destiny” — rather, they help to understand why two outwardly similar trauma histories can result in different biological trajectories.

Why this matters for clinicians and people with PTSD: from biomarkers to therapy

The most practical conclusion of the review sounds simple but changes the perspective: PTSD should be considered a systemic condition in which the psyche and the immune system are linked in a feedback loop. From this, three applied directions emerge. The first is biomarkers. If, following a traumatic event, one tracks not only symptom scales but also inflammatory markers, it may be possible to more accurately identify at-risk groups and assess the dynamics of recovery. It is important to note that in some people, psychological improvement is not always accompanied by the normalisation of cytokines — a signal to look more broadly.

The second direction is therapeutic combinations. The review accumulates data showing that some psychotropic drugs have anti-inflammatory effects, while antihypertensive drugs like ACE inhibitors and angiotensin receptor blockers sometimes reduce the inflammatory background and improve wellbeing in patients with chronic PTSD. In animal experiments, suppressing IL-1β or inhibiting microglial activation reduces anxiety and improves cognitive performance. Transferring these strategies to the clinic requires caution and larger studies, but the vector is clear: it is reasonable to supplement psychotherapy with approaches that “dampen” pathological inflammation.

The third is non-pharmacological interventions that influence the immune circuit. Regular physical activity, sleep normalisation, an anti-inflammatory diet, working with the microbiota, and vagus nerve stimulation — these are not “magic bullets,” but they are justifiable targets that can shift the balance in favour of recovery. The review does not claim that a single diet can “cure PTSD,” but it does stress that somatic practices and behavioural strategies can modulate inflammation and enhance the effect of psychotherapy.

Finally, comorbidity cannot be overlooked. People with PTSD are more likely to face cardiovascular diseases, metabolic syndromes, and autoimmune disorders. From the patient’s perspective, these are not separate issues, but a single story of long-term inflammation that “colours” different systems of the body. From the clinician’s perspective, this is an argument for an interdisciplinary approach: a psychotherapist, psychiatrist, GP, and, where necessary, an immunologist, cardiologist, or endocrinologist. Such a team format increases the chances of not only alleviating symptoms but also reducing long-term risks.

Points to keep in focus

Firstly, PTSD is not “all in the head.” If a person continues to experience fatigue, somatic complaints, and autonomic arousal despite improvement on symptom scales, this is not imagined — it may be a reflection of a persistent inflammatory state. Secondly, inflammation is heterogeneous: cytokine profiles and cellular shifts differ between individuals and over time post-trauma. This explains why standard protocols help some, while others need a more integrative approach. Thirdly, biological markers are not a sentence, but a compass. They help to see a trajectory but do not replace the human context, support, and the processing of meaning from the experience.

One more point, important for hope: neuro- and immune plasticity are real. The fact that dysregulation has occurred does not mean it is irreversible. The combination of psychotherapy with targeted action on inflammation is gradually moving from a hypothesis to a field of active clinical research. As the evidence base grows, specialists have the chance to build personalised plans — for a specific person, their inflammatory phenotype, lifestyle, resources, and goals.

A separate note on methods. Approaches exist that work specifically with traumatic memory and a person’s sense of agency. For example, Mental Engineering as a psychotherapeutic method is aimed at reprocessing traumatic images and restoring a sense of control.

The review by Yang et al. is convincing: trauma is not only the pain of memory but also a long-term shift in the body’s immune language. Acknowledging this does not negate psychological help but expands its possibilities by adding somatic and anti-inflammatory targets. And here is a question with which it is useful to conclude the conversation: if PTSD changes us down to the level of our immune cells, are we ready to change our approach to treatment just as profoundly — from words and meanings to the systemic care of the entire organism?